# Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori

> **NCT04879992** · NA · COMPLETED · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 413 (actual)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Bismuth Potassium Citrate
- **DRUG:** Tetracycline,Metronidazole
- **DRUG:** amoxicillin rifabutin

## Key facts

- **NCT ID:** NCT04879992
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-07
- **Primary completion:** 2022-10-14
- **Final completion:** 2022-10-30
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2022-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04879992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04879992, "Rifabutin-containing Triple Therapy for Treatment of Helicobacter Pylori". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04879992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*